Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …
The biology of erbB-2/nue/HER-2 and its role in cancer
NE Hynes, DF Stern - Biochimica et Biophysica Acta (BBA)-Reviews on …, 1994 - Elsevier
The gene known as neu, erbB-2, or HER-2 is among those most frequently altered in human
cancer, neu was first identified as a transforming gene activated in chemically induced rat …
cancer, neu was first identified as a transforming gene activated in chemically induced rat …
Herceptin: mechanisms of action and resistance
R Nahta, FJ Esteva - Cancer letters, 2006 - Elsevier
HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated with an
aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the …
aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the …
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
This past decade has witnessed the remarkable advances in the understanding of the role of
the erbB2 gene in cancers and the stunning progress in developing targeted therapies for …
the erbB2 gene in cancers and the stunning progress in developing targeted therapies for …
Enhanced c-erbB-2/neu Expression in Human Ovarian Cancer Cells Correlates with More Severe Malignancy That Can Be Suppressed by E1A
Amplification or overexpression of c-erb B-2/neu protooncogene, or both, occur frequently in
many different types of human cancers and have been shown to correlate with decreased …
many different types of human cancers and have been shown to correlate with decreased …
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma
H Itamochi, J Kigawa, N Terakawa - Cancer science, 2008 - Wiley Online Library
Clear cell carcinoma (CCC) accounts for 4% to 12% of epithelial ovarian cancer in Western
countries and, for some unknown reasons, it comprises more than 20% of such cancers in …
countries and, for some unknown reasons, it comprises more than 20% of such cancers in …
[HTML][HTML] Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
Overexpression of the receptor tyrosine kinase p185 ErbB2 confers Taxol resistance in
breast cancers. Here, we investigated the underlying mechanisms and found that …
breast cancers. Here, we investigated the underlying mechanisms and found that …
Molecular mechanisms of erbB2-mediated breast cancer chemoresistance
The erbB2 (also known as HER2 or neu) gene encodes a 185-kDa transmembrane
glycoprotein, which belongs to the epidermal growth factor receptor (EGFR) family. ErbB2 is …
glycoprotein, which belongs to the epidermal growth factor receptor (EGFR) family. ErbB2 is …
HER-2-targeted therapy: lessons learned and future directions
R Nahta, FJ Esteva - Clinical Cancer Research, 2003 - AACR
Abstract HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated
with an aggressive tumor phenotype and reduced survival rates. The HER-2 status of a …
with an aggressive tumor phenotype and reduced survival rates. The HER-2 status of a …
Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial
GN Hortobagyi, NT Ueno, W Xia, S Zhang… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: Preclinical studies have demonstrated that the adenovirus type 5 E1A gene is
associated with antitumor activities by transcriptional repression of HER-2/neu and induction …
associated with antitumor activities by transcriptional repression of HER-2/neu and induction …